Chromadex (NASDAQ: CDXC) and Anthera Pharmaceuticals (NASDAQ:ANTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

10.3% of Chromadex shares are held by institutional investors. Comparatively, 16.7% of Anthera Pharmaceuticals shares are held by institutional investors. 11.6% of Chromadex shares are held by insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Chromadex and Anthera Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -48.68% -52.15% -40.36%
Anthera Pharmaceuticals N/A -18,164.04% -286.30%

Earnings & Valuation

This table compares Chromadex and Anthera Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $21.20 million 12.60 -$11.37 million ($0.25) -19.48
Anthera Pharmaceuticals $140,000.00 56.83 -$26.87 million ($3.31) -0.10

Chromadex has higher revenue and earnings than Anthera Pharmaceuticals. Chromadex is trading at a lower price-to-earnings ratio than Anthera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Chromadex has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Chromadex and Anthera Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 2 0 3.00
Anthera Pharmaceuticals 1 1 2 0 2.25

Chromadex currently has a consensus price target of $7.50, suggesting a potential upside of 54.00%. Anthera Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 1,223.53%. Given Anthera Pharmaceuticals’ higher possible upside, analysts plainly believe Anthera Pharmaceuticals is more favorable than Chromadex.

Summary

Chromadex beats Anthera Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.